Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 58, Issue 12, 2003, Pages 1268-1276

  Van Adelsberg, J ^a,e   Philip, G ^a   Pedinoff, A J ^b   Meltzer, E O ^c   Ratner, P H ^d   Menten, J ^a   Reiss, T F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Princeton Center for Clinical Research   (United States)

^c ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^d Sylvana Research   (United States)

^e NONE   (United States)

Author keywords

Leukotriene antagonist; Montelukast; Seasonal allergic rhinitis; Weekly rhinitis symptoms scores

Indexed keywords

LORATADINE; MONTELUKAST; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ANAMNESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; HUMAN; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RHINOCONJUNCTIVITIS; SKIN TEST;

ACETATES; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LORATADINE; MALE; MIDDLE AGED; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 0345256573     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1398-9995.2003.00261.x     Document Type: Article

References (24)

1. LUNDBACK B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 1998;28 Suppl 2:3-10.
2. MELTZER EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease". Ann Allergy Asthma Immunol. 2000;84:176-187.
3. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N, ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(suppl 5):S147-S334.
4. American Thoracic Society Workshop. Immunobiology of asthma and rhinitis: pathogenic factors and therapeutic options. Am Respir Crit Care Med 1999;160:1778-1787.
5. MELTZER EO, MALMSTROM K, LU S, PRENNER BM, WEI LX, WEINSTEIN SF et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-922.
6. NAYAK A, PHILIP G, LU S, MALICE M-P, REISS TF, Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-600.
7. PHILIP G, MALMSTROM K, HAMPEL JR FC, WEINSTEIN SF, LAFORCE CF, RATNER PH et al. Montelukast for treating seasonal allergic rhinitis: a randomized, doubleblind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-1028.
8. KNORR B, LARSON P, NGUYEN H, HOLLAND S, REISS TF, CHERVINSKY P et al. Montelukast dose selection in 6-to 14-year olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 1999;39:786-793.
9. RATNER PH, LIM JC, GEORGES GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:1101-1107.
10. GROSSMAN J, BRONSKY EA, LANIER BQ, LINZMAYER MI, MOSS BA, SCHENKEL EJ, SEINER JC. Loratadine-pseudoephedrine combination versus placebo in patients with seasonal allergic rhinitis. Ann Allergy 1989;63:317-321.
11. BAROODY FH, NACLERIO RM. Antiallergenic effects of Hi-receptor antagonists. Allergy 2000;55:17-27.
12. JUNIPER EF, GUYATT GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21: 77-83.
13. JUNIPER EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99:S742-S748.
14. STORMS W, MICHELE TM, KNORR B, NOONAN G, SHAPIRO G, ZHANG J et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > 6 years. Clin Exp Allergy 2001;31:77-87.
15. BRONSKY EA, DOCKHORN RJ, MELTZER EO, SHAPIRO G, BOLTANSKY H, LAFORCE C et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:915-921.
16. LAFORCE CF, DOCKHORN RJ, FINDLAY SR, MELTZER EO, NATHAN RA, STRICKER W et al. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract 1994;38:145-152.
17. FINDLAY S, HUBER F, GARCIA J, HUANG L. Efficacy of once-a-day intranasal administration of triamcinolone acetonide in patients with seasonal allergic rhinitis. Ann Allergy 1992;68:228-232.
18. SKONER DP, LEE L, DOYLE WJ, BOEHM S, FIREMAN P. Nasal physiology and inflammatory mediators during natural pollen exposure. Ann Allergy 1990;65:206-210.
19. BAROODY FM, WAGENMANN M, NACLERIO RM. Comparison of the secretory response of the nasal mucosa to methacholine and histamine J Appl Physiol. 1993;74:2661-2671.
20. STRBAN M, MANNING PJ, WATSON RM, O'BYRNE PM. Effect of magnitude of airway responsiveness and therapy with inhaled corticosteroid on histamine tachyphylaxis in asthma. Chest 1994;105:1434-1438.
21. LINDEN M, SVENSSON C, ANDERSSON M, GREIFF L, ANDERSSON E, DENBURG JA et al. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Allergy 1999;54:212-219.
22. MIADONNA A, MILAZZO N, GIBELLI S, SALMASO C, LORINI M, TEDESCHI A. Nasal response to a single antigen challenge in patients with allergic rhinitis - inflammatory cell recruitment persists up to 48 hours. Clin Exp Allergy 1999;29:941-949.
23. WANG D, CLEMENT P, SMITZ J, DE WAELE M, DERDE MP. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995;106:278-285.
24. WINTHER L, MOSEHOLM L, REIMERT CM, STAHL SKOV P, KAERGAARD POULSEN L. Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. Allergy 1999;54:436-445.